VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 106 participants.

Also called NCT03686306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03686306
  • EudraCT 2020-000231-42
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03686306. Randomized; triple masking; primary purpose treatment. Start 2021-11-24 (actual); primary completion 2025-11-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.
Acronym
VIRTUOSE
Condition
Peripheral Artery Disease
Intervention (Drug)
Sildenafil
Intervention (Drug)
Placebo
Lead sponsor
Rennes University Hospital (class: other)

Record details

Record id
cardio:ct-nct03686306
Content hash
57f90c75b9e607c125358aa87efb4d7bb44378bf381589b4c99ca0456dd2689b